MP-E Seminars

“Workshop: Making Pharmaceuticals…Sustainably

Led by Adrian LaPorta / Claire Edwards / Adam Hawthorne

Manufacture and distribution of pharmaceuticals causes significant greenhouse gas emissions. Many leading pharmaceutical companies have pledged impressive remissions reductions but the challenges of implementing these, whilst maintaining or improving access to medicines, are complex.  In this workshop, facilitated  by the institutions of chemical and mechanical engineers and the International Society for Pharmaceutical Engineering (UK affiliate), we invite pharmaceutical  professionals to discuss how to  accelerate the transition to sustainability. We invite you to consider how to:

• Take a holistic view of sustainability in the sphere of pharmaceuticals
• Achieve or help others achieve independently measurable improvements in sustainability
• Inject urgency and move away from a business-as-usual approach
• Co-ordinate effectively with other decarbonisation initiatives
• Maintain the pace of innovation in improving human health, whilst achieving sustainability
• Improve access to medicines, whilst achieving sustainability

Format:

Requirements for attendance:

Because of the style and content of the session attendance will be by invitation with a limited number of attendees. To apply for a workshop place, please complete the following questionnaire, by 3rd April.   (Please note: This information will be kept anonymous.) Only individuals that have registered to attend Making Pharmaceuticals or Distributing Pharmaceuticals as well as completing the workshop application form, will be eligible for a place at the workshop.

There will be a presentation to brief! To achieve deep discussions and development the session will be highly interactive and involve group work and problem solving. The session has three key objectives:

• To examine the challenges we face
• To provide direction [to whom?] for pharmaceutical personnel working in this subject area
• To share new thoughts, ideas, and solutions

Session Duration: 1.25 hours*

Many thanks, The Making Pharmaceuticals and Distributing Pharmaceuticals Organising Team

Please register for the workshop  HERE

Back in 1998, the World Health Organisation (WHO) stated that there were more than 500 deaths worldwide in the previous 60 years caused by use of falsified excipients. Since then, even very recently, further examples have occurred within the supply chain with dramatic impact caused for example by criminal activity, contamination, mislabelling, or upgrading of industrial grade material manufactured under non-GMP conditions.

As a result, the supply chain of pharmaceutical starting materials, in this case excipients, has been identified by regulators and industry as an important part of medicinal product safety. In a globalised world, excipients are supplied across continents and handled by an increasing
number of different parties. The increasing complexity of the global supply chain brings with it an increased risk in excipient security.

This workshop will seek to show how all parties within the supply chain can be supported (e.g. pharmaceutical excipient manufacturers, distributors, traders, brokers, re-packers,
carriers, warehouse providers) and detail some tools which are available to ensure supply chain security and support global drug safety.

Format:

Hear from experts on what’s required to adequately secure the storage and distribution of excipients and join in the discussion as to how this can be demonstrated to the satisfaction of all parties involved. The session has these key objectives:

• To understand that as far as pharmaceutical excipients are concerned, concerns around supply chain security have not gone away.
• There should be controls in place at each interface to ensure excipient security
  upstream as well as downstream within the supply chain.
• With increasing complex supply chains, there are tools including third party certification schemes to complement your knowledge of supply chain pedigrees.

Having registered to attend Making Pharmaceuticals, or Distributing Pharmaceuticals, register your place on the workshop HERE

Overview:

In 2022 a new word just entered the Collins English Dictionary. ‘Permacrisis – an extended period of instability and insecurity’. This will present unique challenges and opportunities to everyone in the Pharma Industry. Important questions must be answered:

• How will companies cut costs (by 30% +) and maintain compliance?
• How will you turn ‘disruptions’ into business advantage?
• What must you stop doing, start doing and do better?
• How will you attract, retain, and develop the best talent?
• How can you educate your team – without a budget?
• How can leaders make the right decisions despite the pressure, stress, and high levels of uncertainty?

Format:

This will be a PowerPoint free zone! To achieve deep learning and personal development the session will be highly interactive and involve group work and problem solving. The session has three key objectives:

• To examine the challenges you face and to answer all your questions
• To summarize what it will take to thrive in a Permacrisis
• To have fun and leave the session buzzing with new thoughts, ideas, and solutions

Session Duration: 2.5 hours

This workshop must be pre-booked, and by individuals who have already registered to attend Making Pharmaceuticals or Distributing Pharmaceuticals.  Applicants will be notified 2 weeks before the event whether they have a place on the workshop.

Please book your place HERE

CellShip® is a novel and potentially disruptive cell transportation and storage medium developed through a highly successful three-year Knowledge Transfer Partnership (KTP) between Life Science Group (LSG) and Coventry University. The Knowledge Transfer Partnership (KTP) is a national programme, partly funded by Innovate UK, designed to help businesses improve their competitiveness and productivity through partnerships with universities.

The KTP between LSG and Coventry University was awarded the highest grade of “Outstanding” by the KTP Grading Panel for its achievement in meeting KTP’s Objectives.

CellShip® is a liquid buffer that allows for the transport of cells at ambient temperatures without the requirement for cryopreservation. This could allow for the shipment of hybridomas, primary cells and other cells between researchers at ambient temperatures while maintaining the integrity and effectiveness of the cells. This product could also be extremely disruptive for cell and gene therapy manufacturing, allowing cells to be delivered to the patient at ambient temperatures without apoptosis that occurs following freeze/thaw cycles. This would also mean that harmful cryoprotectants would not be required.

An important benefit to note is that the protocol requires minimal cell manipulation.

It also reduces the risk of contamination and improves efficiency within the laboratory. To date, Cellship® is validated for up to 120 h of transport/storage at ambient temperatures. It is a cost-effective, safe, novel, and viable alternative to the storage and transportation of cells using standard cryopreservation methods, a useful tool, not only for research purposes but potentially suitable for biomanufacturing and transportation of Advanced Therapy Medicinal Products (ATMPs).